Kybernin P

Antithrombin III, the active ingredient in Kybernin P, is an antithrombin presented as an injectable solution for intravenous use. It replaces deficient antithrombin and is used to prevent clot formation in patients with congenital antithrombin deficiency or during high‑risk surgical procedures.

GNH USA supplies Kybernin P as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Kybernin P, an antithrombin replacement, is used in the coagulation pathway to manage antithrombin deficiency and related thrombotic risk.

- Congenital antithrombin deficiency: restores antithrombin levels to reduce risk of spontaneous thrombosis. - Surgical prophylaxis: prevents thromboembolic events during major surgery or high‑risk procedures. - High‑risk situations (e.g., trauma, immobilization): reduces incidence of clot formation in patients with elevated thrombotic risk.

Kybernin P may cause adverse reactions ranging from mild to severe.

Common Side Effects: - Injection site erythema or pain. - Mild fever or chills. - Headache. - Nausea. - Transient hypotension.

Serious or Rare Side Effects: - Severe bleeding or hemorrhage. - Anaphylactic or severe allergic reactions. - Thrombocytopenia. - Disseminated intravascular coagulation (DIC). - Hemolysis. - Acute renal impairment.

Kybernin P requires careful clinical monitoring to ensure safety and efficacy.

- Antithrombin level monitoring: check activity before and during therapy. - Bleeding risk assessment: evaluate for active bleeding or high‑risk lesions. - Heparin co‑administration: avoid concurrent use unless specifically indicated. - Hypersensitivity: discontinue if signs of severe allergic reaction appear. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kybernin P can interact with other anticoagulant and antiplatelet agents, influencing bleeding risk.

Major Interactions (Avoid): - Heparin and low‑molecular‑weight heparins: may potentiate anticoagulant effect. - Direct thrombin inhibitors: increased risk of excessive anticoagulation.

Moderate Interactions (Monitor Closely): - Warfarin or other vitamin K antagonists: monitor INR and adjust dose. - Antiplatelet drugs (e.g., aspirin, clopidogrel): heightened bleeding tendency. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate gastrointestinal bleeding.